GGrantIndex
← Leaderboards

Judith S Hochman

New York University School Of Medicine

Google Scholar ↗PubMed ↗ORCID ↗
$132,321,589
Attributed
$149,499,691
Total exposure
10
Grants
3
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $41.9M · FY2006–25
$50M$37.5M$25M$12.5M$0
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$253,008,906 · 11

By mechanism

UL1$113,116,392 · 6
U01$111,251,430 · 2
U10$18,561,769 · 1
R01$10,079,314 · 1
KL2$1 · 1

Top collaborators

Most similar at New York University School Of Medicine

Same institution · by research overlap

Others in their field

Top investigators on “Medical”

Research focus

MedicalClinical ResearchCaringResearch PersonnelUnited StatesQuality Of LifeBaseNew YorkResourcesCommunitiesDesignUniversitiesCollaborationsProgramsClinical TrialsTranslatingClinical PracticeFollow-UpRandomizedRecording Of Previous EventsClinical SciencesAwardMyocardial InfarctionEnsure

Grant awards (57)

Clinical and Translational Science Award$7,889,196
UL1 · FY2025 · TR
The International Study of Comparative Health Effectiveness with Medical and Invasive Approaches (ISCHEMIA) trial EXTENDed Follow-up (EXTEND)$2,119,490
R01 · FY2025 · HL · contact PI
Clinical and Translational Science Award$8,534,948
UL1 · FY2024 · TR
The International Study of Comparative Health Effectiveness with Medical and Invasive Approaches (ISCHEMIA) trial EXTENDed Follow-up (EXTEND)$1,952,501
R01 · FY2024 · HL · contact PI
Clinical and Translational Science Award$8,534,948
UL1 · FY2023 · TR
Long-term Suppressive Valacyclovir Treatment for Herpes Zoster Ophthalmicus$2,127,591
U10 · FY2023 · EY
The International Study of Comparative Health Effectiveness with Medical and Invasive Approaches (ISCHEMIA) trial EXTENDed Follow-up (EXTEND)$1,911,200
R01 · FY2023 · HL · contact PI
Clinical and Translational Science Award$8,534,948
UL1 · FY2022 · TR
The International Study of Comparative Health Effectiveness with Medical and Invasive Approaches (ISCHEMIA) trial EXTENDed Follow-up (EXTEND)$1,984,101
R01 · FY2022 · HL · contact PI
Long-term Suppressive Valacyclovir Treatment for Herpes Zoster Ophthalmicus$679,231
U10 · FY2022 · EY
Clinical and Translational Science Award$20,343,524
UL1 · FY2021 · TR
Clinical and Translational Science Award$10,981,872
UL1 · FY2021 · TR
Clinical and Translational Science Award$8,278,789
UL1 · FY2021 · TR
The International Study of Comparative Health Effectiveness with Medical and Invasive Approaches (ISCHEMIA) trial EXTENDed Follow-up (EXTEND)$2,112,022
R01 · FY2021 · HL · contact PI
Clinical and Translational Science Award$136,787
UL1 · FY2021 · TR
Clinical and Translational Science Award$2,218,427
UL1 · FY2020 · TR
Long-term Suppressive Valacyclovir Treatment for Herpes Zoster Ophthalmicus$1,985,974
U10 · FY2020 · EY
Clinical and Translational Science Award$768,511
UL1 · FY2020 · TR
Clinical and Translational Science Award$25,279
UL1 · FY2020 · TR
Clinical and Translational Science Award$5,339,024
UL1 · FY2019 · TR
Long-term Suppressive Valacyclovir Treatment for Herpes Zoster Ophthalmicus$3,278,651
U10 · FY2019 · EY
Project-005$1,653,245
UL1 · FY2019 · TR
Project-004$1,600,403
UL1 · FY2019 · TR
Project-003$1,508,269
UL1 · FY2019 · TR
The Ischemia Trial - CCC$655,855
U01 · FY2019 · HL · contact PI
Project-002$577,107
UL1 · FY2019 · TR
The Ischemia Trial - CCC$16,799,198
U01 · FY2018 · HL · contact PI
The Ischemia Trial - CCC$7,920,000
U01 · FY2018 · HL · contact PI
Clinical and Translational Science Award$5,567,181
UL1 · FY2018 · TR
Long-term Suppressive Valacyclovir Treatment for Herpes Zoster Ophthalmicus$3,873,755
U10 · FY2018 · EY
Long-term Suppressive Valacyclovir Treatment for Herpes Zoster Ophthalmicus$867,421
U10 · FY2018 · EY
The Ischemia Trial - CCC$18,967,704
U01 · FY2017 · HL · contact PI
Clinical and Translational Science Award$5,591,188
UL1 · FY2017 · TR
Long-term Suppressive Valacyclovir Treatment for Herpes Zoster Ophthalmicus$2,849,146
U10 · FY2017 · EY
Clinical and Translational Science Award$384,977
UL1 · FY2017 · TR
The Ischemia Trial - CCC$5,489,839
U01 · FY2016 · HL · contact PI
Clinical and Translational Science Award$5,339,023
UL1 · FY2016 · TR
Long-term Suppressive Valacyclovir Treatment for Herpes Zoster Ophthalmicus$2,900,000
U10 · FY2016 · EY
Clinical and Translational Science Award$146,487
UL1 · FY2016 · TR
The Ischemia Trial - CCC$13,681,446
U01 · FY2015 · HL · contact PI
Clinical and Translational Science Award$4,894,106
UL1 · FY2015 · TR
The Ischemia Trial - CCC$13,546,604
U01 · FY2014 · HL · contact PI
Institutional Clinical and Translational Science Award$4,149,172
UL1 · FY2014 · TR
Institutional Clinical and Translational Science Award$118,981
UL1 · FY2014 · TR
Institutional Clinical and Translational Science Award$1
KL2 · FY2014 · TR
The Ischemia Trial - CCC$6,272,137
U01 · FY2013 · HL · contact PI
The Ischemia Trial - CCC$11,262,237
U01 · FY2012 · HL · contact PI
The Ischemia Trial - CCC$5,554,437
U01 · FY2011 · HL · contact PI
Occluded Artery Trial: Long Term Follow-Up$565,630
U01 · FY2010 · HL · contact PI
Occluded Artery Trial: Long Term Follow-Up$660,947
U01 · FY2009 · HL · contact PI
Occluded Artery Trial: Long Term Follow-Up$782,108
U01 · FY2008 · HL · contact PI
Occluded Artery Trial: Long Term Follow-Up$842,231
U01 · FY2007 · HL · contact PI
OCCLUDED ARTERY TRIAL--CLINICAL COORDINATING CENTER$1,009,138
U01 · FY2006 · HL · contact PI
OCCLUDED ARTERY TRIAL--CLINICAL COORDINATING CENTER$908,004
U01 · FY2003 · HL
OCCLUDED ARTERY TRIAL--CLINICAL COORDINATING CENTER$756,867
U01 · FY2002 · HL
OCCLUDED ARTERY TRIAL--CLINICAL COORDINATING CENTER$1,554,161
U01 · FY2001 · HL
OCCLUDED ARTERY TRIAL--CLINICAL COORDINATING CENTER$4,022,887
U01 · FY2000 · HL